BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 15987991)

  • 1. Promising new advances in head and neck radiotherapy.
    Harari PM
    Ann Oncol; 2005; 16 Suppl 6():vi13-vi19. PubMed ID: 15987991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cetuximab in the management of locoregionally advanced head and neck cancer: expanding the treatment options?
    Bourhis J; Lefebvre JL; Vermorken JB
    Eur J Cancer; 2010 Jul; 46(11):1979-89. PubMed ID: 20561781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cetuximab combined with radiotherapy: an alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck?
    Bernier J; Schneider D
    Eur J Cancer; 2007 Jan; 43(1):35-45. PubMed ID: 17098420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
    Bonner JA; Harari PM; Giralt J; Azarnia N; Shin DM; Cohen RB; Jones CU; Sur R; Raben D; Jassem J; Ove R; Kies MS; Baselga J; Youssoufian H; Amellal N; Rowinsky EK; Ang KK
    N Engl J Med; 2006 Feb; 354(6):567-78. PubMed ID: 16467544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).
    Prawira A; Brana-Garcia I; Spreafico A; Hope A; Waldron J; Razak AR; Chen EX; Jang R; O'Sullivan B; Giuliani M; Bayley A; Cho J; Wang L; Perez-Ordonez B; Weinreb I; Siu LL; Hansen AR
    Invest New Drugs; 2016 Oct; 34(5):575-83. PubMed ID: 27289242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cetuximab in squamous cell head and neck carcinomas.
    Gebbia V; Giuliani F; Valori VM; Agueli R; Colucci G; Maiello E
    Ann Oncol; 2007 Jun; 18 Suppl 6():vi5-7. PubMed ID: 17591832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer.
    Argiris A; Duffy AG; Kummar S; Simone NL; Arai Y; Kim SW; Rudy SF; Kannabiran VR; Yang X; Jang M; Chen Z; Suksta N; Cooley-Zgela T; Ramanand SG; Ahsan A; Nyati MK; Wright JJ; Van Waes C
    Clin Cancer Res; 2011 Sep; 17(17):5755-64. PubMed ID: 21750205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic Review and Meta-analysis of Conventionally Fractionated Concurrent Chemoradiotherapy versus Altered Fractionation Radiotherapy Alone in the Definitive Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma.
    Gupta T; Kannan S; Ghosh-Laskar S; Agarwal JP
    Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):50-61. PubMed ID: 26454839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
    Burtness B
    Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck.
    Bernier J; Bonner J; Vermorken JB; Bensadoun RJ; Dummer R; Giralt J; Kornek G; Hartley A; Mesia R; Robert C; Segaert S; Ang KK
    Ann Oncol; 2008 Jan; 19(1):142-9. PubMed ID: 17785763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck.
    Montejo ME; Shrieve DC; Bentz BG; Hunt JP; Buchman LO; Agarwal N; Hitchcock YJ
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e845-52. PubMed ID: 21167654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck.
    Frampton JE
    Drugs; 2010 Oct; 70(15):1987-2010. PubMed ID: 20883055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
    Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
    Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of combined treatment with cetuximab (erbitux) and radiation therapy in patients with head and neck cancer.
    Koukourakis G; Kouloulias V; Koukourakis M; Kouvaris J; Zacharias G; Gouliamos A
    J BUON; 2009; 14(1):19-25. PubMed ID: 19373942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
    Bonner JA; Harari PM; Giralt J; Cohen RB; Jones CU; Sur RK; Raben D; Baselga J; Spencer SA; Zhu J; Youssoufian H; Rowinsky EK; Ang KK
    Lancet Oncol; 2010 Jan; 11(1):21-8. PubMed ID: 19897418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multidisciplinary approach to squamous cell carcinomas of the head and neck: an update.
    Bernier J
    Curr Opin Oncol; 2008 May; 20(3):249-55. PubMed ID: 18391622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines.
    Bernier J; Russi EG; Homey B; Merlano MC; Mesía R; Peyrade F; Budach W
    Ann Oncol; 2011 Oct; 22(10):2191-200. PubMed ID: 21606209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current concepts of management in radiotherapy for head and neck squamous-cell cancer.
    Mazeron R; Tao Y; Lusinchi A; Bourhis J
    Oral Oncol; 2009; 45(4-5):402-8. PubMed ID: 19375379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.
    Herbst RS; Langer CJ
    Semin Oncol; 2002 Feb; 29(1 Suppl 4):27-36. PubMed ID: 11894011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recent advances in molecular-targeted drugs in head and neck cancer].
    Tahara M
    Gan To Kagaku Ryoho; 2008 May; 35(5):745-52. PubMed ID: 18487911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.